Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Julie Kanter, MD, Darla Liles, MD, Rodolfo Cancado, MD, PhD, João Friedrisch, MD PhD, Troy H. Guthrie, MD, Jennifer Knight-Madden, MBBS, PhD, Ofelia A. Alvarez, MD, Victor R. Gordeuk, MD, Sandra Gualandro, MD PhD, Marina Pereira Collela, MD PhD, Wally R. Smith, MD, Scott A. Rollins, PhD, Jonathan W. Stocker, PhD, Russell P. Rother, PhD

Blood (2016) 128 (22): 1.

https://doi.org/10.1182/blood.V128.22.1.1

Published: 2016

Journal Articles

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Barbara Muz, PhDMSc, Feda Azab, B.Pharm, Pilar De La Puente, PhD, Scott A Rollins, PhD, Richard Alvarez, MBA, Ziad Kawar, PhD, Abdel Kareem Azab, BPharm, PhD

Blood (2014) 124 (21): 4758.

https://doi.org/10.1182/blood.V124.21.4758.4758

Published: 2014

Journal Articles

Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease

Jonathan W. Stocker, PhD, Debra Mandarino, MD, Ziad Kawar, PhD, Richard Alvarez, MBA, David Falconer, MS, MBA, Scott A. Rollins, PhD, Russell P. Rother, PhD

Blood (2013) 122 (21): 970.

https://doi.org/10.1182/blood.V122.21.970.970

Published: 2013

Journal Articles

Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy.

Monica Bessler, MD, PhD, Hubert Schrezenmeier, MD, Jaroslaw P. Maciejewski, MD PhD, Anita Hill, MB ChB, Scott A. Rollins, PhD, Neal S. Young, MD, Lucio Luzzatto, MD

Blood (2007) 110 (11): 840.

https://doi.org/10.1182/blood.V110.11.840.840

Published: 2007

Journal Articles

The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Peter Hillmen, MB, PhD, Petra Muus, MD, PhD, Ulrich Dührsen, DM, Antonio M. Risitano, MD, PhD, Jörg Schubert, MD, Neal S. Young, MD, Hubert Schrezenmeier, MD, Jeffrey Szer, MB, BS, Robert A. Brodsky, MD, Anita Hill, MB, MD, Gérard Socié, MD, PhD, Scott A. Rollins, PhD, Russell P. Rother, PhD, Leonard Bell, MD, Lucio Luzzatto, MD

Blood (2006) 108 (11): 123.

https://doi.org/10.1182/blood.V108.11.123.123

Published: 2006

NARROW

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease

Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy.

The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Email alerts

ASH Publications

American Society of Hematology

SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Proteasome Inhibitors

Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease

Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy.

The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only